INTRODUCTION
The prevalence 1,2 and costs 2 of dementia, of which Alzheimer's dementia (AD) 3 is the dominant subtype, are substantial.
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The patient received forty 1.15 atmosphere absolute/50 minutes total treatment time, once per day, 5 days per week, HBOTs in 66 days. After 21 HBOTs the patient reported increased energy/activity level, mood, and ability to draw a correct clock face, perform activities of daily living, and work crossword puzzles. Rivastigmine patch was started and discontinued after one week due to ineffectiveness (patient report). At completion of 40 HBOTs patient reported increased memory and concentration, sleep, conversation, appetite, ability to use the computer, more good days (5/7) than bad days, resolved anxiety, and decreased disorientation and frustration. Tremor, deep knee bend, tandem gain, and motor speed were improved. Repeat
18
FDG PET imaging one month post HBOT showed global 6.5-38% improvement in brain metabolism (Additional Videos 2-6; Additional Tables 1-3) .
Texture analysis demonstrated a global decrease in the coefficient of variation (CV) except in the Alzheimer's typical ROIs (Additional Tables 4 and 5) . Two months post-HBOT the patient felt a recurrence in her symptoms. She was retreated over the next 20 months with 56 HBOTs (total 96) at the same dose, supplemental oxygen, and medications with stability of her symptoms and Folstein Mini-Mental Status exam (Additional Table 6 ).
DISCUSSION
AD is a debilitating, costly, rapidly increasing neurological disorder for which there is no effective treatment. [1] [2] [3] Etiology is multifactorial, systemic, and immune health-related from insults that occur across the spectrum of life, 13 resulting in reductions of brain regional metabolism.
14 Causes include infection, 13 diabetes mellitus, 13 metabolic disorders, 7 and vascular factors. 15, 16 Four pathological processes have been identified 17 : vascular hypoperfusion of the brain (and disturbed microcirculation) 18 with associated mitochondrial dysfunction, 6 2) destructive protein inclusions (intracellular neurofibrillary tangles--phosphorylated and aggregated tau protein), and extracellular amyloid plaques, 7 3) uncontrolled oxidative stress, and 4) proinflammatory immune processes 13, 19 secondary to microglial and astrocytic dysfunction in the brain. While the vast majority of cases are sporadic, genetic predisposition 20 and epigenetic changes have been implicated. 21 Diagnosis is clinical and can be confirmed with 18 FDG PET hypometabolism in established disease, 22 but is less reliable in mild cognitive impairment. [22] [23] [24] Primary treatment is with acetylcholinesterase inhibitors or the N-methyl-D-aspartate receptor antagonist memantine 5 which have been shown to have positive impact on AD progression 25 with no significant disease-modifying effects. 26 HBOT is an epigenetic 12 modulation of gene expression and suppression 8, 9 to treat wounds 9 and disease pathophysiology, 27 ,28 particularly inflammation. 29 HBOT targets all four of the pathological processes of AD by: 1) affecting the microcirculation 28,30-34 mitochondrial dysfunction 35, 36 and biogenesis, 37, 38 2) reducing amyloid burden and tau phosphorylation, 39 3) controlling oxidative stress, 40 and 4) reducing inflammation. 29, 39, [41] [42] [43] AD was suggested by SPECT and confirmed after rapid clinical decline by 18 FDG PET hypometabolism in the typical temporal-parietal and posterior cingulate areas. 14, 22, 24 Forty
HBOTs improved symptoms and resting global brain metabolism (6.5-38%), including the watershed and posterior cingulate areas. The largest increases were seen in the anterior and mid-cingulate cortices and the least in the posterior cingulate and watershed areas. To our investigation these results are the largest reported global and regional improvements in resting brain metabolism in AD. Test/retest in normal has shown 0.48-9.85% increases in metabolism over 7-23 weeks, 44 25 weeks, 45 and 17 days, 46 while acetylcholinesterase inhibitors treatment has demonstrated regional increases, 47, 50 no change, 48 or decreases [47] [48] [49] in resting metabolism. The largest increase in global metabolism (26.5%) was seen after 26 weeks of rivastigmine in responders during an activation task, but not in the temporal-parietal watershed or cingulate areas. 51 At the same time, texture results were mixed with a global decrease in CV 52 except for the watershed areas which showed the opposite effect. This reduction in CV has corresponded to a visual pattern of smooth texture on SPECT seen in normal individuals and individuals with traumatic brain injury and post-traumatic stress disorder, 52 carbon monoxide poisoning, 53 ,54 decompression sickness, 55 near-drowning, 56 and cerebral palsy 56 after both a single HBOT and course of HBOT. It suggests a non-specific global effect on different brain wounding/pathologies. The differential effect on CV and less robust metabolism increases in the watershed regions implies that the patient's symptomatic improvement may be primarily due to HBOT effects on the rest of the brain. Regardless, HBOT in this patient may be the first drug to not only halt, but temporarily reverse disease progression in AD.
In conclusion, a 9-week treatment of low-pressure HBOT (40 sessions) in a patient with AD caused a significant increase in global metabolism on 18 FDG PET imaging with concomitant symptomatic improvement. Mild symptomatic regression was treated with intermittent HBOT, normobaric oxygen, and medications to stabilize symptoms, suggesting the possibility of long-term HBOT treatment of AD with pharmacotherapy. literature research, data acquisition, data analysis, manuscript preparation, manuscript editing, and manuscript review: PGH and EFF.
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